How a Medical Device OEM Sourced Custom Cable Assemblies from China

When a mid-sized medical device OEM in North America needed to replace its incumbent cable assembly supplier — a domestic manufacturer whose pricing had risen 35% over three years — the procurement and quality engineering team faced a challenge familiar to many device makers: how do you safely transition a critical, patient-applied cable assembly to a new medical cable assembly manufacturer in China without compromising your regulatory compliance or device quality?

This case study describes the process that team followed over a seven-month qualification journey: defining selection criteria, identifying candidates, conducting ISO 13485 quality audits, managing the prototype and first article approval process, setting up production quality controls, and achieving a successful production launch. The lessons learned apply to any medical device OEM considering a similar sourcing transition.

Background: The Device and the Cable

The device was a portable bedside patient monitor used in step-down units and general wards. The cable in question was a 5-lead ECG monitoring trunk cable and leadwire set — a Type BF applied part per IEC 60601-1, requiring dielectric withstand testing at 1,500 Vac and patient leakage current below 100 µA. The cable incorporated a custom 7-pin connector on the monitor end and standard snap-type electrode connectors on the leadwire ends.

Annual volume was approximately 12,000 sets. The incumbent domestic supplier’s pricing of $28 per set had risen to $38 over three years, driven primarily by labor costs. The procurement team’s target was to reduce landed cost to below $20 per set while maintaining full regulatory compliance and quality performance (incoming acceptance rate above 99%).

Step 1: Defining the Supplier Qualification Criteria

Before issuing a single RFQ, the quality engineering team documented a formal supplier qualification checklist. The checklist covered four domains:

Quality Management System Requirements

• ISO 13485:2016 certification, scope covering cable assembly manufacturing, issued by an IAF-accredited body, current surveillance audits confirmed
• Documented design control procedure (even for manufactured-to-print parts, the supplier’s process for handling drawing ECOs must be controlled)
• Process validation records for critical processes: crimp force monitoring, hi-pot testing, overmolding
• Calibrated test equipment with current records for all measurement tools
• Non-conforming material control procedure with physical quarantine capability
• Corrective action procedure with evidence of effective CAPA closure

Technical Capability Requirements

• Demonstrated experience manufacturing IEC 60601-1 compliant patient-applied cables
• 100% hi-pot testing capability at 1,500 Vac (not sampling)
• Custom overmolding capability for the proprietary monitor-end connector boot design
• RoHS 2 and REACH SVHC compliance documentation capability
• ISO 10993-5 cytotoxicity data available for cable jacket and overmold materials

Business and Supply Chain Requirements

• Minimum 5 years in business; medical cable manufacturing as a core business, not a sideline
• Production capacity of at least 50,000 cable sets per year (headroom above current volume)
• Established supply relationships for custom connectors of the type required
• References from at least two current OEM customers in medical devices

Commercial Requirements

• Target landed cost below $20 per set at 12,000 annual volume
• Lead time under 5 weeks for repeat production orders
• MOQ acceptable for annual procurement strategy (quarterly or semi-annual orders)

Step 2: Identifying and Screening Candidates

The team identified six candidate medical cable assembly manufacturers in China through a combination of industry referrals, trade show contacts, and a targeted RFQ process. Of the six, four could provide ISO 13485 certificates. All four certificates were independently verified with the issuing certification bodies — one was found to have expired, reducing the shortlist to three.

Each of the three remaining candidates received an identical RFQ package including the cable assembly drawing, material specifications, annual volume projections, and a supplier qualification questionnaire requesting QMS documentation, equipment lists, customer references, and sample product photos. Based on responses, two candidates progressed to the next stage: a virtual quality audit.

Step 3: ISO 13485 Quality Audit

The quality engineering manager conducted 4-hour virtual audits of each finalist via video conference. Both audits were structured around the ISO 13485:2016 clause structure, with particular focus on:

Clause 7.5 — Production Controls

Both suppliers demonstrated validated crimp force monitoring processes with documented Cpk values above 1.33 — a good indicator of process capability. One supplier could show process validation for the hi-pot test fixture; the other had not formally validated hi-pot test equipment placement or dwell time consistency. The quality engineer flagged this as a risk requiring corrective action before production approval.

Traceability Demonstration

Each supplier was asked to pull the production records for a specific historical lot — lot number provided by the auditor from a previously shipped sample — and walk through the complete traceability package: incoming material acceptance record, batch cutting record, crimp process record, test record, and shipping record. One supplier had complete records retrievable within 15 minutes. The other could retrieve most records but the incoming material acceptance records for that lot were partially incomplete due to a records management system migration.

Non-Conformance Handling

Both suppliers were asked to walk through their non-conforming material (NCM) process, including showing the physical quarantine area and a sample NCM report with disposition. The quarantine areas of both suppliers were adequately labeled and physically separated from conforming stock. The quality of the NCM reports differed: one supplier had detailed root cause analysis with 8D-style documentation; the other had brief descriptions without systematic root cause methodology.

Based on the audits, both suppliers received conditional approval — contingent on corrective actions being closed before first article submission. The supplier selected for progression had the stronger traceability records and more systematic NCM process, despite the hi-pot validation gap which was closed within two weeks with a formal process validation summary.

Step 4: Prototype and First Article Approval

Five prototype sets were ordered for design verification. Nexharn Connectivity’s engineering team and the OEM’s design engineering team collaboratively reviewed the cable drawing to identify potential manufacturability issues before tooling was cut. Two issues were identified and resolved:

• The overmold wall thickness at the monitor connector strain relief entry was below the minimum recommended for reliable injection fill at the specified PU durometer. The drawing was revised to increase wall thickness by 0.4 mm — a change that did not affect the external envelope but improved overmold reliability.
• The conductor color coding specified by the OEM used a non-standard sequence not available from the conductor supplier’s standard stock program. After confirming the functional purpose of the color coding (polarity identification, not clinical significance), the OEM accepted the supplier’s standard color sequence for the minor (non-cardiac) leads, saving 3 weeks of custom conductor lead time.

First article samples arrived 19 days after drawing approval. The OEM’s quality laboratory performed the following acceptance tests:

• 100% dimensional verification against 14 drawing dimensions using calibrated fixtures
• Hi-pot testing at 1,500 Vac for 1 second on all 5 samples — all passed
• Patient leakage current measurement at maximum rated supply voltage — 22 µA maximum, well within 100 µA limit
• Connector insertion and extraction force — within specified range on all samples
• Cable flex life — 5,000 cycles at 90° bend radius over strain relief; no electrical failures
• Disinfectant exposure — 30 wipe cycles with isopropyl alcohol and with quaternary ammonium; no jacket cracking or delamination

All 5 samples passed. First article approval was issued with one observation (minor burr on the inside diameter of the connector boot mold cavity — required preventive action, not rejection). The supplier issued a corrective action within 5 days confirming mold rework had been performed.

Step 5: Production Quality Control Setup

Before releasing the first production order, the quality engineering teams agreed on a production Quality Control Plan covering:

• In-process controls: Crimp force monitoring with SPC charting on every crimping station; visual inspection under 5× magnification at conductor termination; connector housing seating verification using a tactile go/no-go gauge.
• End-of-line testing: 100% continuity and insulation resistance testing; 100% hi-pot testing at 1,500 Vac; 100% connector insertion force spot-check (10% sample rate on final product).
• Documentation: Lot-traceable batch production records including material lot numbers, machine IDs, operator IDs, and test results; Certificate of Conformance issued with each shipment.
• Incoming inspection at OEM: Reduced to 20-piece AQL 1.0 sampling for the first 3 production lots, transitioning to skip-lot after the third consecutive conforming lot.

Results: 18 Months Post-Launch

Eighteen months after the first production order, the OEM’s cable assembly program at the China-based manufacturer had delivered:

• Cost reduction: Landed cost of $17.40 per set — 38% below the previous domestic supplier’s final pricing and below the $20 target.
• Quality performance: Incoming acceptance rate of 99.6% across 8 production lots and approximately 18,000 sets received — above the 99% target.
• Lead time: Average production lead time of 22 days from purchase order to ship — consistently below the 35-day contracted lead time.
• Regulatory readiness: Complete documentation packages supporting the OEM’s 510(k) annual report update and European Technical File maintenance; zero documentation-related issues during a notified body surveillance audit.

Key Lessons Learned

The procurement and quality engineering team identified five practices that were critical to the successful outcome:

1. Verify certifications independently: One of the initial six candidates had an invalid certificate that looked legitimate. 15 minutes of verification saved months of wasted qualification effort.
2. Audit before sampling, not after: Investing in the quality audit before first article tooling ensured that any QMS gaps were corrected before money was committed to production tooling.
3. Invest in DFM review: The two drawing changes identified in the prototype phase would have caused production delays if discovered after tooling was approved. Early engineering collaboration with the supplier prevented this.
4. Agree on the QC Plan in writing before first production order: Ambiguity in inspection requirements is the most common source of disputes between OEMs and overseas suppliers. A written QC Plan eliminates it.
5. Start incoming sampling high, earn skip-lot: Beginning with 100% incoming testing and transitioning to AQL sampling after demonstrated performance created the right incentive structure while protecting the OEM’s production supply.

If your medical device program is evaluating medical cable assembly manufacturers for a new or transferred program, or exploring sourcing from a China cable assembly supplier, the Nexharn Connectivity team is available to walk through your specific cable requirements and quality documentation needs. Contact us with your cable specifications and program timeline to start the conversation.